Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
17.41
-0.91 (-4.97%)
NASDAQ· Last Trade: May 14th, 3:08 PM EDT
Detailed Quote
Previous Close
18.32
Open
17.81
Bid
17.41
Ask
17.46
Day's Range
17.39 - 18.08
52 Week Range
17.03 - 31.26
Volume
431,716
Market Cap
837.10M
PE Ratio (TTM)
8.576
EPS (TTM)
2.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
581,481
Chart
About Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing injectable and inhalation products. The company is dedicated to providing high-quality medicines, particularly in the areas of complex generics and niche products, which include both branded and generic formulations. Amphastar's research and development efforts are geared towards addressing unmet medical needs and improving patient outcomes, with a strong emphasis on innovative therapies and cost-effective solutions in various therapeutic areas. Through its commitment to quality and regulatory standards, Amphastar aims to deliver safe and effective pharmaceuticals to healthcare providers and patients around the world. Read More
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the comp...
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
Bill Peters, chief financial officer of Amphastar
Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, promptin...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year at $171.2 ...
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors sho...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.7% in the afternoon session after Jefferies downgraded the stoc...
Over the last six months, Amphastar Pharmaceuticals’s shares have sunk to $22.73, producing a disappointing 6.3% loss - a stark contrast to the S&P 500’s 5.8...
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have seen decent returns lat...
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Looking back on generic pharmaceuticals stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amphastar Pharmaceuticals (NASDAQ...
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH)
fell 15.8% in the afternoon session after the company reported fourth-quarter 2025 financial results that fell short of Wall Street's expectations on both revenue and profit.
